Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.52 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.52 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.52 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.52 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.48 |
| ▸ | GGPS1 | O95749 | 4/20 | 0.47 |
| ▸ | FDPS | P14324 | 1/20 | 0.47 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
| ▸ | KDM5A | P29375 | 3/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.44 |
| ▸ | KDM5C | P41229 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29174000 | 0.97 | LMNA (0.57) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL1241235 | 0.97 | SMN1; SMN2 (0.52) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL1403908 | 0.97 | LMNA (0.57) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL4880552 | 0.97 | LMNA (0.57) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL1403868 | 0.97 | LMNA (0.57) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL23016786 | 0.97 | LMNA (0.57) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL10398804 | 0.97 | LMNA (0.57) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL7626625 | 0.97 | LMNA (0.57) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL20756484 | 0.97 | LMNA (0.57) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL27685183 | 0.97 | LMNA (0.57) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1120117-B1 | Method of increasing the production of eggs and strengthening eggshells in poultry | CEVA SANTE ANIMALE (FR) | 2007-09-12 | — | — | EP | claimed |
| CN-1277545-C | Use of bisphosphonates in the treatment of bone metastases associated with prostate cancer | NOVARTIS AG (CH) | 2006-10-04 | — | — | CN | claimed |
| CN-1535152-A | Use of bisphosphonates for the treatment of pain | ��˹��ŵ�� | 2004-10-06 | — | — | CN | claimed |
| CN-1384749-A | Use of diphophonic acid in treatment of vasculogenesis | NOVARTIS AG (CH) | 2002-12-11 | — | — | CN | claimed |
| EP-1120117-A1 | Method of increasing the production of eggs and strengthening eggshells in poultry | CEVA SANTE ANIMALE (FR) | 2001-08-01 | — | — | EP | claimed |
| US-20230320995-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | CAPSTAN THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| EP-3150235-B1 | BONE FILLER COMPOSITION | DEPUY INT LTD (GB) | 2018-08-01 | — | — | EP | disclosed |
| EP-2976360-A1 | THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER | Ganymed Pharmaceuticals AG (DE) | 2016-01-27 | — | — | EP | disclosed |
| US-20150157649-A1 | LONG TERM SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING AQUEOUS SUSPENSION OF BISPHOSPHONATE | INTERNATIONAL MEDICATION SYSTEMS, LIMITED | 2015-06-11 | — | — | US | disclosed |
| US-20150157650-A1 | LONG TERM SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING AQUEOUS SUSPENSION OF BISPHOSPHONATE | INTERNATIONAL MEDICATION SYSTEMS, LIMITED | 2015-06-11 | — | — | US | disclosed |
| US-8974801-B2 | Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate | AMPHASTAR PHARMACEUTICALS INC. (US) | 2015-03-10 | — | — | US | disclosed |
| EP-1790347-B1 | High dose ibandronate formulation | HOFFMANN LA ROCHE (CH) | 2014-12-24 | — | — | EP | disclosed |
| CN-1202828-C | Use of diphophonic acid in treatment of vasculogenesis | NOVARTIS AG (CH) | 2005-05-25 | — | — | CN | disclosed |
| CN-1384749-A | Use of diphophonic acid in treatment of vasculogenesis | NOVARTIS AG (CH) | 2002-12-11 | — | — | CN | disclosed |
| EP-1120117-A1 | Method of increasing the production of eggs and strengthening eggshells in poultry | CEVA SANTE ANIMALE (FR) | 2001-08-01 | — | — | EP | disclosed |
| EP-1117411-A1 | PROCESS FOR THE PREPARATION OF ORAL PHARMACEUTICAL COMPOSITIONS COMPRISING BIPHOSPHONATES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000021541-A1 | PROCESS FOR THE PREPARATION OF ORAL PHARMACEUTICAL COMPOSITIONS COMPRISING BIPHOSPHONATES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-04-20 | — | — | WO | disclosed |
| US-5853759-A | Effervescent alendronate formulation | MERCK & CO.. INC. (US) | 1998-12-29 | — | — | US | disclosed |
| US-5735810-A | A MEDICAL EQUIPMENT FOR TRANSDERMAL DRUG DELIVERING A THERAPEUTIC DRUG TREATING BONE DISORDER OSTEOPOROSIS | BECTON DICKINSON AND COMPANY (US) | 1998-04-07 | — | — | US | disclosed |
| US-5730715-A | BONE DISORDERS | BECTON DICKINSON AND COMPANY (US) | 1998-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150157650-A1 | LONG TERM SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING AQUEOUS SUSPENSION OF BISPHOSPHONATE | SOST, PTH1R, BPGM | SMN1; SMN2 198/4885LMNA 4276/4885ALDH1A1 2919/4885 |
| US-20230320995-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | PLTP, LNPEP, PLIN3 | SMN1; SMN2 2768/4885LMNA 41/4885ALDH1A1 4315/4885 |
| US-20150157649-A1 | LONG TERM SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING AQUEOUS SUSPENSION OF BISPHOSPHONATE | SOST, PTH1R, BPGM | SMN1; SMN2 198/4885LMNA 4276/4885ALDH1A1 2919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.